ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis.

Nakajima, A

ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. [electronic resource] - Leukemia Jun 2001 - 989-90 p. digital

Publication Type: Letter

0887-6924

10.1038/sj.leu.2402137 doi


Antineoplastic Agents--pharmacology
Apoptosis--drug effects
Benzamides
Blast Crisis--pathology
Drug Screening Assays, Antitumor
Enzyme Inhibitors--pharmacology
Fusion Proteins, bcr-abl--antagonists & inhibitors
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--pathology
Neoplasm Proteins--antagonists & inhibitors
Oncogene Proteins v-abl--antagonists & inhibitors
Phosphorylation--drug effects
Piperazines--pharmacology
Precursor Cell Lymphoblastic Leukemia-Lymphoma--pathology
Protein Processing, Post-Translational--drug effects
Pyrimidines--pharmacology
Substrate Specificity
Tumor Cells, Cultured--drug effects